

"Pioneering non-endoscopic diagnostics for early detection of gastrointestinal disease"
Cyted is a leading gastrointestinal health company that has created a minimally invasive diagnostic platform to detect esophageal cancer and precancerous conditions early. The company's EndoSign capsule sponge device enables safe, accessible cell collection with full esophageal sampling, paired with advanced molecular diagnostics to identify Barrett's Esophagus and Esophageal Adenocarcinoma. The platform transforms access to digestive health care for patients with chronic heartburn or reflux symptoms. By enabling early detection in community and primary care settings, Cyted addresses a critical gap where fewer than 10% of esophageal cancer patients receive a prior diagnosis.


63
Team Members
2018
Founded
Diagnostics
Sector
Hybrid
Work Environment
A world where esophageal cancer is detected early enough to save lives, with minimally invasive diagnostics accessible to everyone, everywhere, regardless of location or healthcare setting.
At Cyted, our mission is to save lives through early disease detection using our non-endoscopic diagnostic technology.